Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend income, lower volatility relative to growth funds, and near-zero cost structure. When the broader market buckled in early 2026, that positioning paid off: VTV held up far better than growth benchmarks through the first quarter. By mid-July 2026, the fund had extended those gains to roughly 15.3% year-to-date, as value stocks continued to attract capital in an environment where rate uncertainty and geopolitical turbulence kept investors cautious about high-multiple tech names.

What VTV Is Actually Built to Do

VTV tracks the CRSP US Large Cap Value Index, which uses a multi-factor scoring system combining price-to-book, forward earnings, historical earnings, dividend yield, and sales-to-price ratios to identify stocks trading at a discount to intrinsic worth. The fund holds 326 companies, carries a 0.03% expense ratio, and yields roughly 1.9% in dividends. Its total net assets have grown to approximately $254.5 billion, cementing its place as one of the largest pure-value ETFs available.

The return engine is simple in concept: own mature, cash-generating businesses at below-market multiples, collect dividends, and benefit as valuations normalize. No options overlays, no leverage, no synthetic exposure.

The sector mix has shifted meaningfully since the fund’s early-2026 snapshot. Financials now lead at 22.4%, followed by Technology at 15.3% and Healthcare at 15.2%. Those three sectors account for roughly 53% of the portfolio, with Industrials at 14.3%, Consumer Defensive at 8.7%, and Energy at 6.9% rounding out the defensive tilt. Notably, the Technology weighting has climbed from around 10% earlier in 2026 to over 15%, driven largely by Micron Technology’s ascent to the fund’s top holding at 4.85% of assets. Despite that shift, VTV still carries far less tech concentration than growth-oriented peers, where the sector often exceeds 40%.

On Bogleheads forums and Reddit investing communities, VTV is frequently cited as the “value half” of a barbell strategy paired with Vanguard Growth ETF (VUG), or used alongside Vanguard S&P 500 ETF (VOO) for investors who want to tilt toward cheaper valuations without abandoning diversification.

Does the Performance Hold Up?

Over the past decade, VTV returned 207% while the Nasdaq 100 returned 436%. Growth won decisively. Over five years the gap narrows: VTV gained 66% versus the Nasdaq 100’s 82%. Investors who held VTV gave up meaningful upside during bull markets but experienced far less volatility during sharp corrections, a tradeoff that resonates especially with retirees drawing on their portfolios.

The top holdings illustrate both the appeal and the complexity of value investing. Micron Technology is now the fund’s largest position at 4.85%, a semiconductor name that screens as value on a forward earnings basis despite its cyclicality. JPMorgan Chase (NYSE:JPM | JPM Price Prediction), the second-largest position at 3.04%, delivered FY2025 net income of $57.0 billion with EPS of $20.02, supported by strong asset management and markets revenue. Johnson & Johnson (NYSE:JNJ) sits at 2.27% of the portfolio and has been one of VTV’s steadier contributors.

UnitedHealth Group (NYSE:UNH) illustrates how the value trap narrative can evolve. Earlier in 2026 the stock was a drag on the fund, weighed down by a surging medical care ratio, cyberattack costs, a CEO transition, and DOJ scrutiny over Medicare Advantage billing practices. By Q2 2026, however, UnitedHealth posted adjusted EPS of $6.38, beating estimates by 30%, as its medical benefit ratio dropped to 86.7%, the lowest in eight quarters. Management raised full-year 2026 adjusted EPS guidance to $19.50 to $20.00. DOJ investigations remain open with no clear resolution timeline, which keeps meaningful uncertainty in the stock. UNH now represents 1.41% of VTV, up from 1.03% earlier in the year as its share price partially recovered.

AbbVie (NYSE:ABBV) adds a different dimension: a dividend yield near 2.8% and 12 consecutive years of dividend increases, but a trailing P/E distorted by IPR&D charges and negative book value from its acquisition history. Its forward P/E of roughly 15x suggests the business trades more cheaply than the headline multiple implies, with successor drugs Skyrizi and Rinvoq more than compensating for the ongoing decline of Humira.

Three Tradeoffs Worth Understanding

1. Structural growth lag: VTV systematically excludes high-multiple companies. During extended periods when the market rewards earnings growth over current valuation, the fund will trail broad benchmarks. The decade-long return gap versus the Nasdaq 100 reflects this directly.
2. Passive value trap exposure: Index-based value ETFs cannot distinguish between a stock that is cheap because it is misunderstood and one that is cheap because the business is deteriorating. UNH’s earlier collapse while remaining a top-20 holding demonstrates this concretely, even though UNH’s Q2 2026 recovery shows conditions can shift. Diversification across 300-plus names limits the damage from any single holding but does not eliminate it.
3. Interest rate sensitivity in financials: With 22.4% of the portfolio now in financials, VTV carries heightened exposure to the rate cycle. The Federal Reserve held its benchmark rate at 3.50% to 3.75% at its June 2026 meeting, a unanimous decision under new Chair Kevin Warsh, marking the fourth consecutive hold. The updated Summary of Economic Projections turned more hawkish, with nine of eighteen participants penciling in at least one rate hike before year-end. That posture, aimed at bringing inflation back toward the 2% target, creates a more complex backdrop for bank earnings than the easing cycle anticipated earlier in the year.

VTV suits investors who want broad exposure to large, established American businesses at reasonable valuations, a dividend yield near 1.9%, and a lower-volatility profile during growth-led corrections. Its total net assets have grown to $254.5 billion, a reflection of steady inflows from income-oriented investors who value its 0.03% expense ratio and passive discipline. Anyone primarily seeking capital appreciation over a long horizon should weigh the persistent return gap against growth benchmarks before treating this as a standalone holding.

Editor’s note: This article has been updated to reflect VTV’s current net assets of approximately $254.5 billion, revised sector weights as of June 30, 2026 (Financials 22.4%, Technology 15.3%, Healthcare 15.2%), the addition of Micron Technology as the fund’s new top holding at 4.85%, UNH’s Q2 2026 earnings recovery and raised full-year guidance, an updated AbbVie dividend yield of approximately 2.8%, JPMorgan Chase’s confirmed FY2025 net income of $57.0 billion with EPS of $20.02, and a corrected description of the Federal Reserve’s rate stance, which has held at 3.50% to 3.75% through four consecutive meetings under new Chair Kevin Warsh rather than cutting rates as previously stated.

Contact [email protected] for any questions or corrections.